HomeComparePLMNF vs PFE

PLMNF vs PFE: Dividend Comparison 2026

PLMNF yields 1360.54% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLMNF wins by $289773575.33M in total portfolio value
10 years
PLMNF
PLMNF
● Live price
1360.54%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$289773575.38M
Annual income
$253,168,980,206,495.62
Full PLMNF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PLMNF vs PFE

📍 PLMNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPLMNFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PLMNF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PLMNF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PLMNF
Annual income on $10K today (after 15% tax)
$115,646.26/yr
After 10yr DRIP, annual income (after tax)
$215,193,633,175,521.28/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PLMNF beats the other by $215,193,633,153,201.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PLMNF + PFE for your $10,000?

PLMNF: 50%PFE: 50%
100% PFE50/50100% PLMNF
Portfolio after 10yr
$144886787.71M
Annual income
$126,584,490,116,377.17/yr
Blended yield
87.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PLMNF
No analyst data
Altman Z
-158.1
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PLMNF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPLMNFPFE
Forward yield1360.54%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$289773575.38M$49.6K
Annual income after 10y$253,168,980,206,495.62$26,258.71
Total dividends collected$287081511.84M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PLMNF vs PFE ($10,000, DRIP)

YearPLMNF PortfolioPLMNF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$146,754$136,054.42$9,153$693.39+$137.6KPLMNF
2$2,023,063$1,866,036.26$8,593$849.25+$2.01MPLMNF
3$26,205,794$24,041,115.70$8,336$1,066.78+$26.20MPLMNF
4$319,084,195$291,043,996.06$8,437$1,384.80+$319.08MPLMNF
5$3,653,363,011$3,311,942,922.48$9,013$1,875.40+$3653.35MPLMNF
6$39,348,517,956$35,439,419,534.29$10,306$2,680.72+$39348.51MPLMNF
7$398,831,879,642$356,728,965,428.76$12,820$4,101.38+$398831.87MPLMNF
8$3,805,967,119,415$3,379,217,008,197.71$17,673$6,826.70+$3805967.10MPLMNF
9$34,209,902,031,034$30,137,517,213,260.22$27,543$12,591.86+$34209902.00MPLMNF
10$289,773,575,379,702$253,168,980,206,495.62$49,560$26,258.71+$289773575.33MPLMNF

PLMNF vs PFE: Complete Analysis 2026

PLMNFStock

Palamina Corp., through its subsidiary, Palamina S.A. de C.V., focuses on the exploration of mineral deposits in Mexico, Canada, and Peru. It explores for gold, copper, and silver deposits. The company owns 100% interests in the Usicayos Gold project covering an area of 14,600 hectares, the Bendi Gold project covering an area of 13,400 hectares, the Cori Gold project covering an area of 18,000 hectares, and the Inca Gold project covering an area of 2,600 hectares that are located in south-eastern Peru. It also owns 100% interests in the Tinka iron oxide copper-gold project covering an area of 1,800 hectares located in southern Peru; the Galena Silver Copper project covering an area of 10,300 hectares located at south-eastern Peru; and the El Santuario property located in the Cardonal district, Hidalgo State, Mexico. The company was incorporated in 2015 and is headquartered in Toronto, Canada.

Full PLMNF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PLMNF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PLMNF vs SCHDPLMNF vs JEPIPLMNF vs OPLMNF vs KOPLMNF vs MAINPLMNF vs JNJPLMNF vs MRKPLMNF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.